Enantone-Gyn

Quick links to important sections

Enantone-Gyn

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Enantone-Gyn

Quick Facts

Property Description
Active ingredient Leuprorelin acetate
Form Depot preparation (long-acting injection or implant)
Pharmacological class Gonadotropin-Releasing Hormone Agonist (GnRH Agonist)
General Purpose To achieve reversible suppression of sex hormones
Origin Synthetic nonapeptide analogue

Enantone-Gyn: Definition and Pharmacological Classification

Enantone-Gyn is a prescription medicine containing the single active compound, Leuprorelin (or Leuprorelin acetate). It belongs to the medication class known as GnRH Agonists. Leuprorelin itself is a synthetic nonapeptide analogue of the naturally occurring GnRH, which is a key hypothalamic hormone. In this capacity, the medicine acts as a potent modulator of the pituitary gland’s signaling pathway, which controls reproductive function.

Composition and Depot Formulation Type

The active ingredient, Leuprorelin acetate, is delivered within a depot preparation—a specialized long-acting formulation designed for parenteral administration (injection or implant). This depot system is a core feature differentiating it from short-acting formulations. This architecture ensures the continuous, sustained release of Leuprorelin over an extended period, which is essential for maintaining therapeutic hormone suppression. The structure utilizes a lyophilized powder and a sterile vehicle to provide a consistent, prolonged drug effect.

General Therapeutic Purpose of Leuprorelin

The core function of this GnRH Agonist is to induce a controlled and reversible suppression of the body's major sex hormones, such as estradiol and testosterone. Leuprorelin achieves this by continuously desensitizing the pituitary gland, thereby minimizing the signals that normally stimulate hormone production. The general therapeutic goal is to create a temporary, low-hormone environment, which reduces the hormonal drive behind the growth or activity of hormone-sensitive tissues. This fundamental action is utilized in therapeutic situations where the reduction of these specific hormones provides a clinical benefit.

Regulatory References

  1. GnRH Agonist classification

What side effects are possible with Enantone-Gyn?

Possible side effects and safety information

The safety profile of Enantone-Gyn (leuprorelin acetate) is primarily structured by officially documented adverse reactions classified by frequency and body system. As a GnRH Agonist that suppresses sex hormones, many expected effects are consequences of inducing a hypoestrogenic state.


Frequency and Systemic Classification

The most frequent adverse reactions are typically classified as Very Common (ge1/10) or Common (ge1/100). Very Common effects often include hot flushes (vasomotor symptoms) and injection site reactions (such as pain and induration). Common effects span several System-Organ Classes, including Nervous System Disorders (headache), Gastrointestinal Disorders (nausea, diarrhoea), Musculoskeletal Disorders (arthralgia, myalgia), and Psychiatric Disorders (depression, decreased libido).

Time-Related Safety Patterns

The label documents that a transient flare-up or temporary worsening of symptoms may occur during the first few weeks of therapy due to a temporary rise in hormone levels. Furthermore, long-term use is associated with a risk of decreased bone mineral density (BMD).

Serious Adverse Reactions and Safety Constraints

Official regulatory documents detail rare but clinically serious adverse reactions, including pituitary apoplexy (a rare event typically occurring early in treatment) and rare systemic hypersensitivity reactions. Safety constraints stipulate that the medicine is contraindicated in pregnancy due to the risk of fetal harm from sex hormone suppression. Additionally, warnings address the potential for metabolic changes, such as an increased risk of hyperglycemia and changes in the lipid profile.

Overdose and Emergency Response

Overdose and When to Seek Help for Enantone-Gyn (Leuprorelin Acetate)

The official regulatory profile for an overdosage of Leuprorelin acetate is defined by a lack of specific clinical experience with the effects of an acute overdose. Consequently, regulatory guidance focuses on mandatory immediate actions and supportive care.


Overdose Scope

Domain Official Regulatory Statement
Documented Overdose Presentations No clinical experience with the effects of an acute overdose is formally documented.
Emergency-Response Statements The patient should be monitored closely in the event of overdosage.

Overdose Classifications (High-Level)

Classification Official Regulatory Status / Phrasing
Regulatory Basis Information derived from government-authorized prescribing information (e.g., FDA Prescribing Information and European Summary of Product Characteristics).
Overdose-Context Constraints The information applies to overdosage and subsequent management, which must be symptomatic and supportive.

Official Overdose Statements:

  • Urgent Medical Attention: Urgent medical attention must be sought immediately following a known or suspected overdosage event.
  • Antidote Status: No specific antidote is known or officially documented for leuprorelin acetate overdose.
  • Management Procedure: Management in the event of overdosage should be symptomatic and supportive as a regulator-mandated procedure.

Connection to the overall overdose profile: The regulatory profile is characterized by the explicit absence of documented acute manifestations, which informs the emergency protocol. This situation mandates that any suspected overdosage requires an immediate call for medical attention, with the necessary treatment being strictly limited to symptomatic and supportive care under close clinical observation, exactly as specified by the official regulatory guidance.

Therapeutic Uses of Enantone-Gyn

What Enantone-Gyn Treats: Main Uses and Benefits

The medicine is a therapeutic option used for managing gynecological conditions that present with significant symptoms. It is commonly used to help with severe and disruptive symptoms associated with conditions where functional stability becomes affected. The therapy is applied in contexts involving a heightened systemic burden. Conditions addressed include those involving episodic or fluctuating manifestations, often presenting with systemic or localized discomfort.


Easing Discomfort in Relevant Clinical Settings

This medication provides essential symptomatic support in conditions that cause noticeable physical discomfort. It is applied across domains where additional symptomatic support is needed and helps address symptom clusters that may become intense or disruptive. The benefit is that it may offer temporary assistance in managing symptoms and helps ease the overall symptom burden.

Quick Fact: Helps Address Disruptive Symptom Manifestations


Improving Daily Comfort During High-Symptom Phases

Enantone-Gyn is applied in clinical settings that involve acute or unstable symptom patterns, which require additional management of discomfort. It is commonly used across conditions characterized by periods of heightened symptoms or recurrent manifestations, which often produce a significant symptomatic burden. It contributes to supporting day-to-day comfort during symptomatic periods and may assist patients with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus Drug Information on Leuprolide

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Enantone-Gyn — Official Regulatory Information

This section outlines the eligibility criteria for Enantone-Gyn (Leuprorelin Acetate) based strictly on authoritative governmental regulatory documents.

Populations for Whom Use is Prohibited or Conditional

Category Eligibility Status Detail (As per Official Labeling)
Pregnancy Strictly Contraindicated The medicine must not be used by women who are pregnant or who may become pregnant (a negative pregnancy test is required before starting therapy).
Lactation Contraindicated The medicine must not be used by women who are breastfeeding.
Hypersensitivity Contraindicated Prohibited for patients with a known allergy or severe sensitivity to leuprorelin acetate, GnRH, GnRH agonist analogs, or any other component of the medicine.
Diagnosis Contraindicated Must not be used in women with undiagnosed abnormal vaginal or uterine bleeding until a clear diagnosis is established.

Conditional Use and Restrictions

  • Age: Generally intended for reproductive-aged adult women. It is not indicated for postmenopausal women for these uses.
  • Duration Limit: Use is typically restricted in duration (e.g., often limited to six months) due to the risk of decreased bone mineral density (BMD).
  • Retreatment: Any retreatment is considered conditional and may require prior assessment of BMD and the use of 'add-back' therapy to mitigate bone loss risk.
  • Mental Health: Patients with a history of depression must be closely monitored, as GnRH agonists may cause or exacerbate mood disorders.

Regulatory documents explicitly define these criteria to ensure patient safety and therapeutic suitability, strictly prohibiting use in specific physiological states and limiting therapy duration for all others.

What should I know about interactions with other medicines?

The official regulatory interaction profile for Leuprorelin acetate (Enantone-Gyn) is primarily defined by specific pharmacodynamic constraints and its metabolic pathway.


Pharmacokinetic Interaction Profile

No systemic pharmacokinetic drug-drug interactions are expected. The active ingredient, a peptide, is primarily degraded by peptidases and not by the Cytochrome P-450 (CYP) enzyme system. Therefore, co-administration with medicines that are CYP inhibitors or inducers is not anticipated to alter the systemic exposure of Leuprorelin. No specific timing separation requirements are documented in the labeling for co-administered medicinal products.


Specific Pharmacodynamic Constraints

The following interactions are formally documented in regulatory prescribing information, outlining constraints on co-administration:

Interaction Type Interacting Substance/Class Official Regulatory Statement
Contraindicated GnRH Agonist Analogs Prohibited due to known class hypersensitivity.
Additive Risk Drugs that prolong the QT interval Increased risk for Long QT Syndrome is documented.
Reduced Effectiveness Androgen Therapy May officially result in a reduction of the therapeutic outcome.

Food and Co-Factor Notes

No direct interactions with food, alcohol, or herbal products are specified in official prescribing information. However, chronic alcohol use is noted as a population-specific consideration because it is an established risk factor that may exacerbate the potential for loss of bone mineral density associated with GnRH agonist therapy.

Mechanism of Action

How Enantone-Gyn Works: The Mechanism of Action

The mechanism of Enantone-Gyn (Leuprorelin acetate) involves a two-phase process that modulates the production of sex hormones by acting on the pituitary gland.

Pituitary Receptor Desensitization and Downregulation

The core of the mechanism involves Enantone-Gyn acting as a Gonadotropin-Releasing Hormone ( GnRH) agonist that targets GnRH receptors ( GnRHR) on the anterior pituitary gland. While initially stimulating these receptors, the continuous presence of the drug (due to the depot formulation) results in a functional switch to suppression by causing sustained desensitization and a reduction in the number of active GnRHRs. This loss of receptor responsiveness is the fundamental mechanism that results in the suppression of central signaling.

Sustained Suppression of the Hormonal Axis

The resulting GnRHR downregulation leads to a profound and continuous inhibition of the pituitary's output of signaling hormones: Luteinizing Hormone ( LH) and Follicle-Stimulating Hormone ( FSH). This sustained absence of gonadotropin stimulation causes the gonads (ovaries/testes) to reduce their activity, thereby inducing a systemic hypogonadal state characterized by reduced levels of circulating estradiol and testosterone.

Mechanism Constraint: The Initial Flare Effect

An unavoidable constraint of this agonist mechanism is the initial flare effect, where the drug's initial strong stimulation of existing GnRHRs causes a temporary surge of LH/ FSH and consequently a transient increase in sex hormone levels. The drug's sustained suppression of the axis is dependent on the completion of the necessary receptor downregulation following this initial phase.

Dosage and Administration Information

How Enantone-Gyn is Used: Official Administration Guidelines

Enantone-Gyn is a prescription medicine delivered as a depot suspension for long-acting effect. Usage instructions specify precise routes, dosing schedules, and preparation requirements.


Administration and Dosing

Property Requirement in Official Labeling
Route of Administration Must be given as a single Intramuscular (IM) injection or Subcutaneous (SC) injection by a trained healthcare professional.
Standard Dosing Fixed dose of 3.75 mg every four weeks (monthly) or 11.25 mg every three months.
Preparation The medicine is supplied as a sterile lyophilized powder and must be reconstituted with the accompanying diluent immediately before administration.

Treatment Course and Timing

Official instructions limit the total continuous duration of therapy. For the management of endometriosis, the initial course is typically limited to six months (e.g., six 3.75 mg injections). For uterine fibroids, the recommended duration of therapy is typically limited to up to three months of continuous administration.

Administration must adhere strictly to the scheduled date (monthly or quarterly) to ensure continuous drug suppression. There are generally no specific dose adjustments required for older adults or those with mild to moderate renal or hepatic impairment.

The entire course of therapy, including any retreatment with add-back therapy, is generally limited to a maximum total cumulative duration of 12 months.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase I and II Trials: Initial Safety and Pharmacokinetics

Early-stage research explored whether clinical function is affected in small groups of participants. These initial trials focused primarily on establishing the dose-ranging characteristics and evaluating the overall safety profile of the investigational compound. Studies suggest the compound may exert effects related to blocking key inflammatory pathways involved in the target condition, though this mechanism is still under investigation. Pharmacokinetic studies determined the time the compound takes to reach peak concentration in the blood, which informed the dosing schedule used in later studies.


Phase III Trials: Efficacy and Long-Term Safety

Larger, randomized, controlled Phase III trials expanded on the initial findings, evaluating the compound for its potential to affect pain and inflammation over periods of up to 12 months in hundreds of participants. Research has investigated the time to onset of potential changes in pain scores, with some participants noting changes in mobility scores. For example, a study reported findings related to joint swelling measurements, with the mean change observed at the 6-month endpoint.

The trials included adult participants, and safety findings were collected throughout the study duration. The safety profile was characterized during the trials, with common side effects being hot flashes and headache, consistent with the expected hormonal changes.


Combination and Comparative Studies

Research explored whether the combination formulation is associated with changes in patient compliance and long-term outcomes, compared to the single-compound delivery. The administration requirements used during the study protocols were documented. Studies have compared this formulation against other therapies in controlled research settings; however, no direct head-to-head trials were specifically conducted against every comparable therapy mentioned in the literature, though comparative effectiveness research has been initiated.

Frequently Asked Questions (FAQ)

Common questions about Enantone-Gyn (FAQ)

Q: What happens to my period while I am on Enantone-Gyn?

A: Official product information indicates that an expected effect of this treatment is the stopping of menstrual periods (known as amenorrhea). This occurs as a result of the medicine's mechanism, which involves suppressing sex hormone production. However, some patients may experience a temporary side effect of light, irregular vaginal bleeding or spotting.


Q: Is it normal to have some spotting or bleeding right after the first Enantone-Gyn injection?

A: Light vaginal bleeding or spotting may be experienced by some patients. This is sometimes linked to the drug's initial mechanism, which causes a temporary surge in hormones (called a flare effect) before the long-term hormone suppression begins. The temporary flare effect may, for some, lead to a temporary worsening of symptoms, which could include spotting or bleeding.


Q: Will taking Enantone-Gyn affect my mood or emotional stability?

A: Yes, regulatory documents indicate that mood changes are documented side effects of this treatment. These can include feelings like depression, anxiety, irritability, and emotional lability (unpredictable mood swings). Official warnings state that patients with a history of depression should be closely monitored during treatment.


Q: Does Enantone-Gyn cause weight gain or weight loss for most people?

A: Official information notes that a change in weight (which may be either gain or loss) is a documented side effect of this treatment. Regulatory warnings also note the potential for general metabolic changes while undergoing therapy.


Q: What are the signs that Enantone-Gyn is actually working for my condition?

A: Response to treatment is typically assessed by monitoring clinical symptoms, such as a reduction in pain or a decrease in the size of hormone-sensitive growths. Success is correlated with achieving a continuous state of sex hormone suppression, confirmed through appropriate monitoring determined by your healthcare provider.


Q: What happens if I forget a scheduled Enantone-Gyn injection appointment?

A: Maintaining continuous hormone suppression requires strict adherence to the scheduled dates for the injection. If a scheduled injection appointment is missed or needs rescheduling, official guidelines suggest contacting a healthcare provider immediately to arrange the next administration and minimize disruption to the treatment.


Q: Can Enantone-Gyn be used for fertility treatments or only for conditions like endometriosis?

A: Enantone-Gyn is officially indicated for conditions such as endometriosis and uterine fibroids. However, the active ingredient is also used by specialists in protocols for female infertility to temporarily suppress the natural hormone cycle. The hormonal effect is generally expected to be reversible after treatment is discontinued.


Q: Is Enantone-Gyn an option for treating uterine fibroids?

A: Yes, official labeling indicates that the medicine is used for the treatment of uterine fibroids (leiomyomata). It is often used to treat related symptoms, or to reduce the size of fibroids to simplify a subsequent surgical procedure.


Q: What are the concerns about using Enantone-Gyn in younger patients?

A: While the drug is generally intended for reproductive-aged adults for these indications, a key safety concern for long-term use in all patients is the risk of decreased bone mineral density (BMD). For this reason, treatment duration is closely monitored by a healthcare provider.


Q: Are there any known long-term side effects after stopping Enantone-Gyn treatment?

A: The suppression of the hormonal system is designed to be reversible. However, some clinical literature notes that a small number of patients have reported side effects, such as memory loss or persistent hot flashes, that may last more than six months after stopping treatment.


Q: Can Enantone-Gyn be administered by the patient at home, or only by a healthcare professional?

A: The depot formulation must be prepared and administered as an injection. Official administration guidelines state the injection should be given by, or under the supervision of, a healthcare professional.


Q: Can Enantone-Gyn affect hair growth or cause hair thinning?

A: Yes, official side effect information lists hair loss (or hair thinning) as a documented adverse reaction. Conversely, some rare side effects may include increased hair growth.


Q: Is Enantone-Gyn an option for men, or is it exclusively for gynecological issues?

A: The active ingredient in Enantone-Gyn, leuprorelin, is also used in male patients. The 'Gyn' formulation is specifically indicated for hormone-dependent gynecological conditions, but other formulations of the same active ingredient are used to treat conditions like prostate cancer in men.


Q: What kind of monitoring (e.g., blood tests) is typically needed while on Enantone-Gyn?

A: Monitoring often includes blood tests to assess for signs of metabolic changes, such as those related to lipid profile (cholesterol) and blood glucose levels. If retreatment is considered, an assessment of bone mineral density (BMD) is also required.


Q: Is Enantone-Gyn a cure for endometriosis or just a treatment for the symptoms?

A: The drug's function is to induce a reversible state of hormone suppression, which leads to the temporary regression of hormone-sensitive tissues. Since the effect is generally reversible after stopping the medicine, it is described as a treatment for symptoms and disease progression, rather than a permanent cure.


Q: Do people who have had an allergic reaction to similar drugs need to avoid Enantone-Gyn?

A: Official regulatory documents indicate the medication is contraindicated (prohibited) for patients with a known severe sensitivity or allergy to the active ingredient, any component of the medicine, or other synthetic GnRH analogues (drugs in the same class).


Q: Does Enantone-Gyn have a strong drug interaction with common antibiotics?

A: Systemic drug interactions are not generally expected with common medicines like antibiotics. Regulatory information states that the drug is broken down by peptidases and not by the Cytochrome P-450 (CYP) enzyme system, which is responsible for the metabolism of many common antibiotics.


Q: Will I need to change my diet while taking Enantone-Gyn?

A: Official labeling does not mandate specific diet changes. However, due to the potential for metabolic changes and the risk of decreased bone mineral density, healthcare providers and guidelines often recommend incorporating nutritional changes and physical activity into your lifestyle to help mitigate these potential side effects.


Q: Is there a generic version of Enantone-Gyn available?

A: Enantone-Gyn contains the active ingredient Leuprorelin acetate, which is also found in many other branded products around the world. The availability of a direct, non-branded generic copy of 'Enantone-Gyn' is specific to local pharmaceutical markets and cannot be confirmed globally through regulatory documents alone.


Q: Can Enantone-Gyn be used to prepare for certain types of surgery?

A: Yes, official labeling confirms the drug is indicated for use prior to surgery for conditions like uterine fibroids. It may be used to reduce the size of the fibroids to facilitate a smoother or less invasive surgical procedure.


Q: Is it safe to drive or operate machinery after receiving an Enantone-Gyn shot?

A: Official information advises caution because the medication may cause side effects such as fatigue, dizziness, and visual disturbances. If these symptoms are experienced, it is advised to exercise caution and avoid driving or operating machinery.


Q: How quickly should I expect to see effects after taking Enantone-Gyn?

A: Therapeutic hormone suppression is typically achieved two to four weeks after the very first injection, as this is the time required for the initial temporary hormone surge (flare effect) to pass and for the suppression mechanism to take hold. Patients may start to notice changes in their symptoms once this period has passed.


Q: How long does the effect of one Enantone-Gyn injection typically last?

A: The drug is given as a depot suspension, designed to release the active medicine continuously over an extended period. Drug levels in the bloodstream are sustained for the duration of the scheduled interval (e.g., up to 35 days for a monthly shot) to maintain continuous hormone suppression.


Q: Can Enantone-Gyn affect bone density if used for a long time?

A: Yes, decreased bone mineral density (BMD) is a reported side effect associated with the use of this class of medication. Due to this risk, the official continuous treatment duration is generally restricted to a limited period, as determined by regulatory guidelines.


Q: How long after stopping Enantone-Gyn will my natural menstrual cycle return?

A: The suppression of the hormonal system is designed to be reversible. Official product information indicates that the normal function of your hormonal system, and the potential return of your menstrual cycle, is usually restored within 4 to 12 weeks after the last injection is administered.


Q: Why do some people report headaches or migraines as a side effect of Enantone-Gyn?

A: A headache is listed as a common side effect of the treatment. This is often thought to be related to the expected physiological changes that occur as the treatment induces a hypoestrogenic state (low estrogen levels).


Q: Does Enantone-Gyn affect cholesterol levels?

A: The medicine is officially associated with a risk of metabolic changes. Because of this, healthcare providers typically monitor for these changes, including checking the lipid profile (which involves cholesterol levels) and blood glucose levels during treatment.


Q: Does Enantone-Gyn have any effect on libido or sexual function?

A: Yes, official side effect information includes a decrease in sexual desire or ability (known as decreased libido). This is an expected physiological effect related to the overall suppression of sex hormone levels caused by the medication.

How should Enantone-Gyn be stored and disposed of?

How to Store and Dispose of Enantone-Gyn

Official regulatory documents provide specific instructions for the storage and disposal of this medication, which are critical for maintaining its stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically between 15 C and 25 C.
Protection The product must be protected from freezing. Store in the original package to protect it from light.
Stability The injectable suspension must be prepared immediately before administration and used right away. Do not store the prepared suspension.
Security Keep this medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired medication, including any associated materials, must not be disposed of in household trash or wastewater. Disposal should be carried out according to local pharmaceutical waste regulations, often involving return to a designated pharmacy or collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Enantone-Gyn found in:

A-Z Index: